Akari Therapeutics (AKTX) Accumulated Expenses (2014 - 2026)
Akari Therapeutics recorded quarterly Accumulated Expenses of $888000.0 in Q1 2026, down 62.08% quarter-over-quarter from $2.3 million in Q4 2025, and up 25.07% year-over-year from $710000.0 in Q1 2025.
Akari Therapeutics' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $888000.0 for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 25.07% year-over-year to $888000.0; the TTM figure through Mar 2026 stood at $888000.0 (up 25.07% YoY), while the FY2025 annual figure was $2.3 million, up 395.14% from the prior year.
- Accumulated Expenses came in at $888000.0 for Q1 2026 at Akari Therapeutics, down from $2.3 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $3.1 million in Q4 2022 to a low of $50000.0 in Q2 2025.
- A 5-year average of $1.3 million and a median of $1.1 million in 2022 frame the typical range for Accumulated Expenses.
- On a YoY basis, Accumulated Expenses climbed as much as 395.14% in 2025 and fell as far as 89.08% in 2025.
- Akari Therapeutics' Accumulated Expenses stood at $3.1 million in 2022, then tumbled by 50.25% to $1.6 million in 2023, then slumped by 69.8% to $473000.0 in 2024, then jumped by 395.14% to $2.3 million in 2025, then tumbled by 62.08% to $888000.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $888000.0, $2.3 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 888,000.00 |
| Dec 31, 2025 | 780,000.00 |
| Sep 30, 2025 | 607,000.00 |
| Jun 30, 2025 | 50,000.00 |
| Mar 31, 2025 | 710,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Sep 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 377,000.00 |
| Mar 31, 2024 | 418,000.00 |
| Dec 31, 2023 | 1.57 Mn |
| Jun 30, 2023 | -746,541.00 |
| Dec 31, 2022 | 3.15 Mn |
| Jun 30, 2022 | -1.77 Mn |
| Mar 31, 2022 | 2.45 Mn |
| Dec 31, 2021 | 3.18 Mn |
| Sep 30, 2021 | 1.43 Mn |
| Jun 30, 2021 | 1.56 Mn |
| Mar 31, 2021 | 1.07 Mn |
| Sep 30, 2020 | 975,893.00 |
| Jun 30, 2020 | 1.94 Mn |
| Mar 31, 2020 | 2.63 Mn |
| Dec 31, 2019 | 4.23 Mn |
| Sep 30, 2019 | 3.04 Mn |
| Jun 30, 2019 | 2.67 Mn |
| Mar 31, 2019 | 1.63 Mn |
| Dec 31, 2018 | 1.49 Mn |
| Sep 30, 2018 | 1.71 Mn |
| Jun 30, 2018 | 3.99 Mn |
| Mar 31, 2018 | 4.56 Mn |
| Dec 31, 2017 | 4.80 Mn |
| Sep 30, 2017 | 736,540.00 |
| Jun 30, 2017 | 1.31 Mn |
| Mar 31, 2017 | 1.14 Mn |
| Dec 31, 2016 | 1.84 Mn |
| Sep 30, 2016 | 405,151.00 |
| Jun 30, 2016 | 360,679.00 |
| Mar 31, 2016 | 231,905.00 |
| Dec 31, 2015 | 408,222.00 |
| Sep 30, 2015 | 3.85 Mn |
| Dec 31, 2014 | 42,999.00 |